ORACLE INDUSTRY CONNECT, WASHINGTON DC-March 25, 2015-Alliance for Clinical Trials in Oncology Foundation, a nonprofit organization that supports the mission to reduce the impact of cancer, has selected Oracle’s Siebel Clinical Trial Management System and Oracle Health Sciences IRT as the IT platform for a comprehensive, 10-year clinical study, conducted in partnership with a tier-one pharmaceutical company and sponsored by Alliance Foundation Trials (AFT). The solutions will provide a proven platform for the decade-long study as well as future Alliance research initiatives.
“As part of our mission to reduce the impact of cancer, it is imperative that our clinical trials run as successfully and efficiently as possible. Going into a 10-year study, we need a proven, enterprise-scale clinical trial management infrastructure that we can count on today and into the future,” said Monica M. Bertagnolli MD, president, Alliance for Clinical Trials in Oncology Foundation and chief executive officer, AFT. “Oracle Health Sciences applications provided a competitive solution.”
Siebel Clinical Trial Management System will help AFT ensure the efficiency and integrity of its studies, reducing risk while boosting research team productivity. The organization plans to create a centralized trial management database that provides users with the most relevant information based on their specific roles and responsibilities and is designed to speed access to critical data, improve monitoring and patient safety, and keep data secure. Users can also access the system via any browser from any device, further elevating productivity and the user experience.
The deployment of Oracle Health Sciences IRT is designed to enable AFT to more effectively manage patient randomization and global supply chains by extending interactive voice response (IVR) and interactive web response (IWR) systems. AFT also expects to gain the insight needed to change study parameters midstream while reducing service delivery and change-order costs, and looks to optimize the cost of event charges by leveraging the web in addition to the phone for capture.
AFT will benefit from the scalability, cost-effectiveness, and rapid deployment that cloud-based solutions deliver. It plans to leverage Oracle Health Sciences Cloud for Oracle Health Sciences IRT and a third-party cloud service provider for Siebel Clinical Trial Management System.
“Oracle is pleased to support AFT as it embarks on this important 10-year research study. Oracle Health Sciences solutions provide a highly reliable foundation that helps to drive efficient, effective, and insightful research. Our flexible cloud-based delivery options are designed to help AFT achieve faster time to deployment, lower cost of entry, and ready scalability when needed,” said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.